Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBITION 2
2026-525471-13-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Oct 2026
- Modality
- Small Molecules, Peptides
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Zenagamtide with Placebo (2 arms). Primary endpoint: Change in glycated haemoglobin. Planned start Oct 2026; status: authorised.
02
Drugs
amycretin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2026-525471-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525471-13-00.